MiR-9 mediates the downregulation of BRCA1, impedes DNA damage repair in ovarian cancer and improves chemotherapeutic efficacy by increasing the sensitivity of cancer cells to DNA damage (78). This evidence concerns the gene BRCA1 and ovarian carcinoma.